MyMD Pharmaceuticals (MYMD) Insider Trading & Ownership

$1.80

+0.19 (+11.80%)

(As of 10/15/2024 ET)

Current Insider Ownership Percentage: 2.12%
Number Of Insiders Buying (Last 3 Years): 2
Amount Of Insider Buying (Last 3 Years): $375,368.10
Number Of Insiders Selling (Last 3 Years): 0

Get MYMD Insider Trade Alerts

Want to know when executives and insiders are buying or selling MyMD Pharmaceuticals stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily.

MYMD Insider Buying and Selling by Quarter

Ad Porter & Company

Elon knows the truth, which is why they want him silenced

Elon Musk is one of mankind’s greatest innovators. But for all his visionary prowess and contributions to humanity, there is a war being waged on Elon Musk. This war has nothing to do with X, Elon’s stance on immigration or his support for Donald Trump.

Watch this new documentary and you’ll discover what Elon knows,

MyMD Pharmaceuticals Insider and Congressional Trades History

Transaction Type

Time Frame

Start Date

End Date

Export to Excel

Transaction Date	Name	Title	Buy/Sell	Number of Shares	Average Share Price	Total Transaction
8/24/2023	Paul Rivard	Insider	Buy	5,000	$33.30	$166,500.00
12/8/2022	Paul Rivard	EVP	Buy	333	$45.90	$15,284.70
11/26/2021	Joshua Silverman	Director	Buy	166	$226.50	$37,599.00
11/24/2021	Joshua Silverman	Director	Buy	333	$196.80	$65,534.40
11/23/2021	Paul Rivard	EVP	Buy	500	$180.90	$90,450.00

(Data available from 1/1/2013 forward)

MYMD Insider Trading Activity - Frequently Asked Questions

: The list of insiders at MyMD Pharmaceuticals includes Joshua Silverman, and Paul Rivard. Learn more on insiders at MYMD.
: 2.12% of MyMD Pharmaceuticals stock is owned by insiders. Learn more on MYMD's insider holdings.
: The following insider purchased MYMD shares in the last 24 months: Paul Rivard ($181,784.70).
: Insiders have purchased a total of 5,333 MYMD shares in the last 24 months for a total of $181,784.70 bought.

MyMD Pharmaceuticals Key Executives

Dr. Christopher C. Chapman Jr. (Age 71)
M.D., President, Chief Medical Officer & Director
Compensation: $665.76k
Mr. Ian Rhodes CPA (Age 51)
Interim Chief Financial Officer
Compensation: $162k
Dr. Jenna Brager M.S.
Ph.D., R.N., Executive Vice President of Drug Development